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Abstract
We searched for a drug capable of sensitization of sarcoma cells to doxorubicin (DOX). We report that the dual PI3K/mTOR
inhibitor PI103 enhances the efficacy of DOX in several sarcoma cell lines and interacts with DOX in the induction of
apoptosis. PI103 decreased the expression of MDR1 and MRP1, which resulted in DOX accumulation. However, the
enhancement of DOX-induced apoptosis was unrelated to DOX accumulation. Neither did it involve inhibition of mTOR.
Instead, the combination treatment of DOX plus PI103 activated Bax, the mitochondrial apoptosis pathway, and caspase 3.
Caspase 3 activation was also observed in xenografts of sarcoma cells in nude mice upon combination of DOX with the
specific PI3K inhibitor GDC-0941. Although the increase in apoptosis did not further impact on tumor growth when
compared to the efficient growth inhibition by GDC-0941 alone, these findings suggest that inhibition of PI3K may improve
DOX-induced proapoptotic effects in sarcoma. Taken together with similar recent studies of neuroblastoma- and
glioblastoma-derived cells, PI3K inhibition seems to be a more general option to sensitize tumor cells to anthracyclines.
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Introduction
Sarcomas are a heterogeneous group of malignant tumors of
mesenchymal origin. More than 50 histological subtypes are
known. Sarcomas comprised 1% of malignancies in adults but
15% in patients under 20 years old in North America in 2006 [1]
and 8.5% of cancers in European patients aged 15–24 years
diagnosed from 1990 to 1994 [2]. Thus, sarcomas are in general
more prevalent in children. The most common histological
sarcoma subtype in children is rhabdomyosarcoma (RMS) [3].
Sarcomas present a therapeutic challenge compared with other
solid tumors both because of the limited success of traditional
treatment approaches and because monitoring the response of
sarcoma lesions to therapy is not straightforward [1]. The
treatment of sarcomas usually comprises surgical resection,
radiation treatment, and chemotherapy. Chemotherapy of sarco-
mas frequently involves anthracyclines, which are topoisomerase II
(TOP2) inhibitors, in combination with other cytostatic drugs
[4,5]. One of the anthracyclines used in the therapy of sarcoma is
DOX.
There remain unresolved issues associated with DOX use in
sarcoma therapies. For example, the original phase II trials
performed in RMS patients showed response rates between only
18% and 37% [6–8], while a response rate of 65% was reported in
a more recent phase II study of patient with high-risk metastatic
RMS [9]. Randomized phase III studies conducted by the North
American Intergroup Rhabdomyosarcoma Study Group have
investigated the addition of DOX to VAC (vincristine, actinomy-
cin D and cyclophosphamide) chemotherapy for patients with
Clinical Group III and IV RMS, but have failed to show any
evidence of efficacy [10–12]. The lack of evidence of superiority of
DOX with VAC over VAC alone and the potential for
cardiotoxicity have limited the widespread use of DOX in the
initial treatment of RMS. Since young children are particularly
susceptible to anthracycline-induced cardiotoxicity, careful use of
DOX is especially relevant [13,14].
The efficacy of DOX in sarcoma therapies could be improved
by combination with drugs other than those comprising VAC. To
identify drugs enhancing antitumoral effects of DOX in sarcoma,
we performed a screen using the sarcoma cell line HT1080. The
screen included the proteasome inhibitor bortezomib, the DNA-
demethylating agent 5-Aza-Deoxycytidin (5-Aza), the histone
deacetylase inhibitor valproic acid (VPA) and the PPARy ligand
pioglitazone. All these drugs have been shown to sensitize other
tumor entities to antitumoral effects of TOP2A inhibitors,
purportedly by increasing TOP2A expression levels [15–21].
Additionally, we used the dual PI3K and mTOR inhibitor PI103.
This was due to the fact that sarcomas frequently show activation
of PI3K/Akt/mTOR signaling [22,23] and dual PI3K/mTOR
inhibitors sensitize neuroblastoma and glioblastoma cells to DOX-
induced apoptosis [24,25].
PLOS ONE | www.plosone.org 1 December 2012 | Volume 7 | Issue 12 | e52898Our present study was prompted by the observation that PI103
interacts with DOX in the induction of apoptosis and in activation
of caspase 3 in 3 different sarcoma cell lines. Since these
proapoptotic effects were in contrast to recent data for the dual
PI3K/mTOR inhibitor NVP-BEZ23 in sarcoma cells, we in-
vestigated the underlying mechanism in more detail.
Materials and Methods
Reagents
DOX and bortezomib were dissolved in 0.9% NaCl. 5-Aza and
VPA were dissolved in PBS and pioglitazone, PI103, zVAD.fmk
and LY294002 in DMSO, and everolimus in ethanol. GDC-0941,
a PI103 analog [26], was obtained from Genentech Inc. (San
Francisco, California, USA) and dissolved in Methylcellulose-
Tween-Solution (MTS) or DMSO for in vivo or in vitro application,
respectively.
Cell Culture
The human RMS cell line RD and the human sarcoma cell line
HT1080 were obtained from ATCC. The murine RMS cell line
TP5014 was a gift from Professor Torsten Pietsch (Department of
Neuropathology, University of Bonn, Germany). TP5014 is
a stable murine RMS cell line derived from a RMS of a Ptch
neo12/
+ mouse [27] with the consideration of all necessary legal
requirements (no ethics committee approval was required;
personal communication from Torsten Pietsch). All cell lines were
cultured in DMEM, 10% FCS, and 1% penicillin/streptomycin.
Medium used to culture HT1080 cells was additionally supple-
mented with 20 mM Hepes, 10 mM sodium pyruvate and 4% (v/
v) non-essential amino acids.
For gene expression analysis and determination of apoptosis 100
000 cells/well were seeded in 6-well-plates. For Caspase-GloH 3/7
and BrdU incorporation assay 5,000 cells/well were seeded in 96-
well-plates. Cells were allowed to settle for 24 h. After washing,
cells were incubated for 24 h with medium supplemented with
drugs or solvent as indicated in the respective experiments. For
pretreatment of the cells with PI103 cells were pretreated with the
drug for 12 h and DOX was added to the same medium for
additional 24 h.
Cell proliferation was measured after BrdU-pulsing for the last
24 h using a Cell Proliferation BrdU ELISA (Roche Diagnostics
GmbH, Mannheim, Germany). Drug-induced BrdU-incorpora-
tion is presented as the percentage of the incorporation measured
in time-matched vehicle-treated controls taken as 100%.
Apoptosis was determined of cells stained with Annexin V-
FITC (BD Biosciences, Heidelberg, Germany) and To-Pro-3
iodide (PI, Invitrogen GmbH, Karlsruhe, Germany) on a FACScan
system (BD Biosciences).
Activity of caspase 3 and 7 was measured using the Caspase-
GloH 3/7 Assay (Promega). The luminescence intensity is shown as
the fold-induction over the control value, which was set to 1.
Data shown are representative for 2 to 8 independent
experiments performed as duplicates.
Quantification of Intracellular Doxorubicin
To measure the intracellular amount of DOX quantitatively,
RD or HT1080 cells were seeded in 6-well-plates (10
5 cells/well).
24 h later, DOX alone, DOX combined with PI103, or PI103
alone were added. After incubation for 24 h, the drug-containing
culture medium was discarded and the cells were washed with
PBS. Cells were gently harvested using accutase and cell pellets
were obtained by low-speed centrifugation (300 g, 5 min, 4uC).
After washing with PBS, cells were collected and DOX
fluorescence was measured by flow cytometry using a FACSCali-
bur (BD Biosciences, Heidelberg, Germany). Excitation wave-
length was 488 nm, and emission wavelength was 530 nm.
Intracellular DOX was quantified in at least 10 000 cells from
each sample.
RNA Extraction, Reverse Transcription and Quantitative
RT-PCR-analyses
Total RNA was isolated using TRIzol Reagent (Invitrogen
GmbH, Karlsruhe, Germany) according to the manufacturer’s
instruction. cDNA was synthesized using Superscript II and
random hexamers (Invitrogen, Karlsruhe, Germany). Quantitative
RT-PCR of target cDNAs was performed using SYBR-green
based assays. Primer pairs used for amplification of MDR1 (59-
GTGGTGGGAACTTTGGCTG/59-TACCTGGT-
CATGTCTTCCTCC) and MRP1 (59-ATGTCACGTGGAA-
TACCAGC/59-GAAGACTGAACTCCCTTCCT) were intron-
spanning. Amplification of 18S rRNA (59- CGCAAATTACC-
CACTCCCG/59-TTCCAATTACAGGGCCTCGAA) served to
normalize any inter-sample differences in the efficiency of reverse
transcription. Real time quantitative RT-PCR analysis was carried
out using the ABI Prism HT 7900 Detection System instrument
and software (Applied Biosystems, Darmstadt, Germany). The
data shown are representative for at least five independent
experiments. Each sample of every experiment was measured as
a triplicate.
Western Blot Analysis
Generally, cells were lysed in a buffer containing 30 mM Tris-
HCl pH 7.4, 150 mM NaCl, 1% Triton X-100, 10% Glycerol,
500 mM PMSF, 2 mM DTT, and a protease inhibitor cocktail.
For detection of MRP1, cells were lysed in a RIPA buffer
containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM
EDTA, 1% NP-40, 0.25% Na-Deoxycholat and the protease
inhibitor cocktail. Protein concentrations were determined by the
Pierce Protein BCA Assay Kit (Themo Fisher Scientific, Rockford,
USA). Antibodies used to detect the individual target proteins are
shown in Table S1.
For detection of active Bax, cells were lysed in CHAPS lysis
buffer (10 mM HEPES (pH 7.4); 150 mM NaCl; 1% CHAPS). A
total of 500 mg protein was immunoprecipitated with 2 mg mouse
anti-Bax antibody (6A7, Sigma) and 5 ml Dynabeads Pan Mouse
IgG (Dako, Hamburg, Germany). The precipitate was analyzed by
western blotting using the BaxNT antibody (Upstate Biotechnol-
ogy) (see also [28]).
All Western blots shown are representative of at least two
independent experiments.
Determination of Cytochrome c Release
Cytochrome c release was determined as previously described
[29,30].
In vivo RD Xenograft Model and Treatment with GDC-
0941 and/or DOX
Nude mice used in the study were handled in accordance with
the German animal protection law and the experiments were
approved by the Niedersa ¨chsisches Landesamt fu ¨r Verbrau-
cherschutz und Lebensmittelsicherheit (permit number:
33.42502-04-09508). Aliquots of 2610
6 viable RD cells in
200 ml PBS/Matrigel (1:1) were injected subcutaneously (s.c.) into
the flank region of the mice. Tumors were measured twice weekly
with calipers, and tumor volumes were calculated by the formula
[length6width6(height/2)] [31]. The body weight and general
PI3K Inhibitors and Doxorubicin in Sarcoma
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Treatment of the animals bearing sarcoma xenografts started
when the tumor’s volume reached 30–60 mm
3.
GDC-0941 was administered orally at the recommended daily
dose of 75 mg/kg body weight for a total of 22 days. DOX at
1.2 mg/kg body weight was administered intraperitoneally (i.p.)
every third day on days 1, 4, 7, 10, 13, 16, 19 and 22. This
continuous low-dose schedule has been shown to moderately but
significantly inhibit the growth of RD xenografts in other studies
[32]. Combined treatment comprised these drugs at the same
doses as in individual treatments. Control animals bearing s.c.
flank tumors were treated with MTS and 0.9% NaCl following the
same schedules.
At the end of the study, tumor nodules were carefully dissected
and fixed in a 4% PFA solution for further analysis. In addition,
tumor regrowth was monitored over a period of 20 days after
withdrawal of the drugs.
Immunohistochemical Analysis
For analysis of caspase 3 activity in the xenotransplants, paraffin
sections were boiled in citrate buffer (pH 6.0) for 45 min. The
endogenous peroxidase was quenched with 3% hydrogen perox-
ide. Staining was done with anti-active caspase 3 (R&D Systems;
1:500 in 10% Casein in TBS, pH 7.4) followed by incubation with
rabbit/mouse Envision HRP ready (DakoCytomation, Hamburg,
Germany). Signals were detected with AEC solution. Thousand
cells of each tumor were evaluated for positive signals. The results
of 7–9 tumors for each treatment group were summarized to
calculate the percentage of positive cells. For TUNEL (Terminal
deoxynucleotidyl transferase dUTP nick end labeling) assay, the
DeadEnd Colorimetric TUNEL System (G7130, Promega) was
used.
Statistical Analysis
Unless indicated otherwise, statistical differences for all experi-
ments using more than two treatment schemes were analyzed
using Tukey’s test in conjunction with ANOVA. When comparing
2 samples, statistical differences were analyzed using Student’s t-
test. Data was considered significant when P,0.05. Interaction
between PI103 and DOX was analyzed by the combination index
(CI) method using CalcuSyn software (Biosoft). CI ,0.9 indicates
synergism, 0.9–1.1 indicates additivity, and .1.1 indicates
antagonism.
Results
Effects of DOX in Combination with 5-Aza, VPA,
Bortezomib, Pioglitazone, or PI103 in Sarcoma Cells
The effects of DOX alone or in combination with candidate
drugs on proliferation, apoptosis, and caspase 3/7 activity (as
measured by Caspase-GloH 3/7 Assay) were investigated in the
sarcoma cell line HT1080. DOX effects were studied at
a concentration of 1 mM, which is within the plasma concentration
of this drug in humans [33,34].
As shown in Table 1, treatment of the cells with 1 mM DOX
resulted in a significant proliferation inhibition by 80%. In
addition, 1 mM DOX significantly increased the numbers of
Annexin V-positive cells to 27% (solvent-treated cells 3%) and
caspase 3/7 activity to 2-fold over the control.
Candidate drugs were applied to HT1080 cells at concentra-
tions described for other cell culture experiments [15–19].
Whereas treatment of the cells with 5-Aza (5 mM) and VPA
(2 mM) significantly induced the proliferation rate of the cells,
bortezomib (10 nM) and PI103 (1 mM) significantly reduced it.
None of the drugs had a significant effect on the number of
Annexin V-positive cells (Table 1). However, bortezomib signif-
icantly induced caspase 3/7 activity.
Next, the drugs were combined with DOX. As shown in
Table 1, DOX-induced proliferation inhibition was significantly
enhanced by bortezomib. The enhancement by PI103 was of
borderline significance (P,0.08). DOX-related apoptosis was also
enhanced by both pioglitazone and PI103, as indicated by the
significant increase of Annexin V-positive cells. In addition, PI103
was able to enhance DOX-mediated induction of caspase 3/7
activity.
In summary, the dual PI3K/mTOR inhibitor PI103 signifi-
cantly affected 2 of the measured parameters of apoptotic cell
death when combined with DOX, i.e. it significantly enhanced the
proapoptotic effects of DOX measured by Annexin V staining and
by Caspase-Glo 3/7 assay. Furthermore, it enhanced DOX-
induced antiproliferative effects (P,0.08). Therefore, we focused
on this compound as a promising combination partner for DOX
and investigated the generality of the combined effects towards
sarcoma cells by including the TP5014 and RD cell lines derived
from murine and human RMS, respectively.
PI103 Interacts with DOX in the Induction of Apoptosis in
Sarcoma Cells
We first assessed whether the dual PI3K/mTOR inhibitor
PI103 blocks PI3K/Akt/mTOR signaling in the cell lines
examined by assessing phosphorylation of Akt and S6 ribosomal
protein taken as surrogate readouts for the activity of PI3K and
mTOR, respectively. As shown in Figure 1A, both RMS cell lines
exhibit intact PI3K/mTOR signaling, as do HT1080 cells. This is
evidenced by phosphorylation of Akt and S6, which was efficiently
decreased by PI103 (Figure 1A). Treatment with 3 mM PI103
almost completely inhibited Akt phosphorylation in all 3 cell lines.
Therefore, this dose was applied in all consecutive experiments.
Besides dephosphorylation of S6 we also observed a decrease in
the total amount of S6 after incubation with PI103. This was in
agreement with previously published data shown for the dual
PI3K/mTOR inhibitor NVP-BEZ235 in breast cancer cells [35].
Next we assessed the antiproliferative and proapoptotic effects
of 3 mM PI103 alone or in combination with DOX in sarcoma
cells. In order to avoid overlooking potential cooperative
antiproliferative effects, the DOX concentration was lowered to
0.5 mM in BrdU assays. The proliferation rate of all cell lines was
decreased by approximately 50% in comparison to untreated
controls (see Figure 1B). Apoptosis was measured at 1 mM DOX.
Both DOX and PI103 alone consistently reduced cell pro-
liferation in all 3 sarcoma cell lines (Figure 1B). When both drugs
were combined, a significant enhancement of DOX-induced
antiproliferative effects was seen in rhabdomyosarcoma cells
(Figure 1B). A calculation of the CI in RD and HT1080 cells
revealed that PI103 synergistically cooperated with DOX to
inhibit proliferation (CI=0.769 and CI=0.766, respectively). In
respect of apoptosis, DOX treatment resulted in a significant
increase of Annexin V positive RD and HT1080 cells. After PI103
treatment, a significant increase was only seen for RD cells
(Figure 1B). This was different when both drugs were combined.
As shown in Figure 1B, the combination treatment resulted in
a strong and significant increase of Annexin V positive cells in all
cell lines examined. When we distinguished between early
(Annexin V
+ PI
2) and late (Annexin V
+ PI
+) apoptotic cells, we
found that the combination treatment increased either of these
cellular subsets to approximately the same extent (Figure S1).
Furthermore, incubation with the broad-range caspase inhibitor
zVAD.fmk almost completely blocked apoptosis upon combined
PI3K Inhibitors and Doxorubicin in Sarcoma
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caspase-dependent (Figure S2). Indeed, in all 3 cell lines, the
increase in Annexin V positive cells was accompanied by an
enhancement of caspase 3 activation, which was revealed by the
occurrence of cleaved and active caspase 3 fragments (Figure 1B).
Together these data demonstrated that the combined treatment
with PI103 and DOX results in enhancement of apoptosis of
sarcoma cells. In the following, we elucidated the mechanism of
the interaction of DOX and PI103 in apoptosis in more detail
using RD cells.
PI103 Inhibits the Expression of DOX Efflux Transporters
and Increases Intracellular DOX Concentrations
The PI3K/Akt signaling has been reported to activate the
expression of the DOX efflux transporters MDR1 (P-gp) in breast
and gastric cancer cells [36,37] and of MRP1 in AML [38] and in
prostate carcinoma cells [39]. Based on these observations we
hypothesized that inhibition of PI3K/Akt activity decreases the
expression of MDR1 and MRP1, leading to DOX accumulation
in the tumor cells.
Indeed, as revealed by FACS analysis in the living cell fraction,
the treatment with 1 mM DOX in conjunction with 3 mM PI103
resulted in intracellular DOX accumulation (Figure 2A). The
accumulation approximately equated that caused by treatment
with 2 mM DOX. Similarly, in HT1080 cells, the DOX-specific
fluorescence after combination treatment with 1 mM DOX plus
3 mM PI103 equated that caused by incubation with 3 mM DOX
(data not shown).
The accumulation of DOX correlated with changes in the
expression of MDR1 and MRP1. As shown in Figure 2B, PI103
resulted in a 60% decrease in the transcription of both MDR1 and
MRP1 mRNA (Figure 2B; left and middle panel). The PI103-
mediated decrease in MRP1 expression was confirmed on the
protein level (Figure 2B; right panel). Unfortunately, the analysis of
MDR1 protein was impossible due to very low basal protein
expression levels in RD cells.
PI103-mediated Intracellular DOX Accumulation is not
Responsible for the Combined Proapoptotic Effect of
PI103 and DOX
We next investigated if the PI103-associated DOX accumula-
tion was responsible for the combined effects of the drugs on
apoptosis. To this end we incubated RD cells with 2 mM DOX.
This resulted in an intracellular DOX accumulation similar to that
following an incubation with 1 mM DOX plus 3 mM PI103 (see
above). Although the treatment with 2 mM DOX increased the
percentage of Annexin V positive cells when compared to 1 mM
DOX, the increase was significantly smaller than that observed
after treatment with 1 mM DOX plus 3 mM PI103 (Figure 2C). In
addition, 2 mM DOX did not enhance caspase 3 activity as did the
combination treatment (Figure 2D). Similar results were obtained
for HT1080 cells (data not shown).
We also analyzed if an additional 12-hours pretreatment with
PI103 enhanced sensitization of sarcoma cells to DOX-induced
anticancer effects. Like the 24-hours incubation, a 36-hours
incubation with PI103 alone significantly induced apoptosis of RD
cells when compared to untreated cells (Figure 2E, left panel). The
pre-exposure further strengthened the sensitization of RD cells to
DOX-mediated anticancer effects. This was not only evident by
a stronger antiproliferative effect (Figure S3A; for HT1080 and
TP5014 cells see Figure S3B and S3C), but also by a further
increase of Annexin V-positive cells (approximately 5-fold
compared to the control; see Figure 2E, left panel) when compared
to the increase of Annexin V positive cells after the 24-hours co-
incubation (approximately 3.5-fold compared to the control; see
Figure 2C, left panel). However, the preincubation with PI103 did
not result in a further increase in DOX accumulation (Figure 2E,
right panel). Together, these data indicated that the enhancement
of DOX-induced apoptosis by PI103 cannot solely be explained by
PI103-associated DOX accumulation.
Combination Treatment with PI103 and DOX Induces Bax
Activation and Enhances Cytochrome c Release
PI103 has been recently reported to cooperate with DOX to
shift the ratio of pro- and antiapoptotic Bcl-2 proteins finally




Annexin V positive cells
(%)
Increase caspase 3/7 activity
(over solvent)
Drug Concentration
DOX 1 mM 280%* 27%* 2-fold*
5-Aza 5 mM +80%* 3% 1.4-fold
DOX/5-Aza 1 mM/5 mM 260%
# 31%* 2.1-fold
VPA 2m M +50%* 3.6% 1.8-fold
DOX/VPA 1 mM/2 mM 270%* 33.7%* 2.8-fold*
bortezomib 10 nM 270%* 10% 4.9-fold*
DOX/Borte 1 mM/10 nM 290%
# 40%* 1.5-fold
pioglitazone 10 mM +10% 2.4% 1-fold
DOX/Pio 1 mM/10 mM 290%* 42.5%
# 1.4-fold
PI103 1 mM 210%* 2.5% 0.9-fold
DOX/PI103 1 mM/1 mM 290%* 53%
# 5-fold
#
Proliferation of HT1080 cells was measured by BrdU incorporation. Shown is the increase or decrease in comparison to vehicle-treated cells. Apoptosis was analyzed by
FACS of Annexin V positive cells and caspase 3/7 activity was measured by Caspase-GloH 3/7 assay. Statistical significance was assessed by ANOVA/Tukey’s method.
*P,0.05 compared to cells treated with solvent; #P,0.05 compared to cells treated with either drug alone. Numbers in bold indicate cases, where given drug
combination inhibited proliferation or induced apoptosis to a larger extent than either drug alone.
doi:10.1371/journal.pone.0052898.t001
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Activated Bax translocates to the mitochondrial membranes,
where it causes the loss of mitochondrial membrane potential and
subsequent cytochrome c release and caspase activation [40].
Activation of Bax goes along with a conformational change in its N
terminus in the cytosol, which precedes Bax translocation to the
Figure 1. PI103 sensitizes RD cells to DOX-induced apoptosis. A) Levels of phospho-Akt, Akt, phospho-S6 ribosomal protein and S6
ribosomal protein were measured by Western blot analyses in RD, TP5014 and HT1080 cells after treatment with 1 mMo r3mM PI103 as indicated. B)
Upper panel: Proliferation was estimated by BrdU incorporation after treatment with 0.5 mM DOX and/or 3 mM PI103. Middle panel: Apoptosis was
analyzed by FACS after treatment with 1 mM DOX and/or 3 mM PI103 or solvent. Data represent mean+SEM of at least three independent
experiments performed in triplicates. Comparisons were made with ANOVA/Tukey’s testing. *P,0.05 compared to cells treated with solvent;
#P,0.05 compared to cells treated with either drug alone. Lower panel: Protein levels of phospho-Akt, Akt and caspase 3 in cells treated with 1 mM
DOX and/or 3 mM PI103 or respective solvents.
doi:10.1371/journal.pone.0052898.g001
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conformation-specific anti-Bax antibody 6A7 [28,41].
We first investigated the effect of PI103 and DOX on Bax
activation by immunoprecipitation of protein lysates with anti-Bax
antibody 6A7 and subsequent analysis by western blotting using
BaxNT antibody as previously described [28]. Secondly, we
investigated the related cytochrome c release by means of FACS
analysis using the cytochrome c-specific antibody 7H8.2C12. This
antibody does not detect cytosolic cytochrome c after apoptosis
induction [30]. Therefore, the reduction in the cytochrome c
signal reflects mitochondrial cytochrome c release and early onset
of apoptosis.
As revealed by Western Blot analysis, DOX did not alter Bax
activity, whereas PI103 marginally changed the conformation of
Bax. However, the effect on Bax activation was strongly enhanced
when both drugs were combined (Figure 3A). Bax activation after
PI103/DOX co-treatment was also demonstrated in TP5014 and
HT1080 cells (Figure S4A and S4B). A similar result was seen
when cytochrome c release into the cytosol was studied. Whereas
monotherapy with PI103 had a moderate effect on cytochrome c
release, the combination with DOX strongly enhanced this effect
(Figure 3B).
Together these data demonstrate that the combined effect of
PI103 plus DOX involves Bax activation and cytochrome c
release.
The Specific PI3K Inhibitor LY294002, but not the mTOR
Inhibitor Everolimus, Enhances DOX-induced Apoptosis
Next, we investigated to what extent the combined proapoptotic
effects of PI103 plus DOX were mediated by mTOR or by PI3K.
To this end, we treated RD cells with the specific mTOR inhibitor
everolimus or with the specific PI3K inhibitor LY294002 alone or
in combination with DOX. The data shows that everolimus
neither significantly increased the DOX-induced percentage of
Annexin V positive cells nor induced caspase activity (Figure 4A
left panel, and Figure 4B left panel, respectively). This was not due
to lack of activity of everolimus, because the drug efficiently
reduced phosphorylation of the mTOR target S6 (Figure 4B left
panel). However, we also observed that everolimus increased
phosphorylation of Akt. This phenomenon has been demonstrated
previously by several groups in several cancer cell lines including
RD cells [35,42,43]. In contrast, LY294002 significantly increased
DOX-induced apoptosis as revealed by Annexin V labeling
(Figure 4A right panel) and by increased caspase activity (Figure 4B
right panel). The combined proapoptotic effect also correlated
with Akt dephosphorylation, which was not seen upon single drug
treatment.
Together the data show that mTOR inhibition does not
significantly affect DOX-induced apoptosis and suggest that the
proapoptotic effects of a combination treatment using DOX plus
a dual PI3K/mTOR inhibitor such as PI103 mainly involves
inhibition of PI3K, but not of mTOR.
Figure 2. PI103-induced DOX accumulation does not account for cooperative proapoptotic effects in RD cells. A) Intracellular DOX
autofluorescence after treatment with 1 mM DOX (red line), 3 mM PI103 (black line), 2 mM DOX (blue line), 1 mM DOX plus 3 mM PI103 (green line) or
solvent (orange line) at 530 nm. The data are expressed as the percentage of the maximum (max) number of positive cells. B) Expression levels of
MDR1 (left panel) and MRP1 (middle panel) after treatment with 3 mM PI103 in relation to solvent treated cells (set=1). Data represent mean+SEM of
at least five independent experiments performed in triplicates. *P,0.05 by Students t-test. Protein level of MRP1 after treatment with 3 mM PI103 or
the solvent (right panel). C) Annexin V positive RD cells were analysed after treatment with 1 mM DOX, 3 mM PI103, 1 mM DOX plus 3 mM PI103, 2 mM
DOX or the solvent. Data represent mean+SEM. Comparisons were made with Students t-test. D) Cells were treated as in C and caspase 3 was
assessed by Western blot analyses. E) Annexin V positive RD cells (left panel) and intracellular DOX autofluorescence (right panel) after a 12-hours
pretreatment (preinc.) with 3 mM PI103 and subsequent addition of 1 mM DOX for additional 24 h. Annexin V data represent mean+SEM.
Comparisons were made with Students t-test.
doi:10.1371/journal.pone.0052898.g002
Figure 3. PI103 and DOX cooperate in Bax activation and cytochrome c release. RD cells were treated with 1 mM DOX and/or 3 mM PI103
or the solvent. A) Activation of Bax was analysed by immunoprecipitation. B) Cytochrome c release was assessed by FACS at 530 nm (red line: 1 mM
DOX; green line: 3 mM PI103; orange line: 1 mM DOX plus 3 mM PI103; black line: solvent). The data are expressed as the percentage of the maximum
(max) number of positive cells and represent one of three independent experiments, measured in duplicates.
doi:10.1371/journal.pone.0052898.g003
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Enhance DOX-induced Antitumor Effects Despite
Increased Caspase 3 Activity
The solubility of PI103 is limited and the compound is
metabolized extensively. Therefore, its use in in vivo studies is
limited [26]. An optimization program focused on improving
pharmaceutical properties of PI103 has led to the development of
GDC-0941. In comparison to PI103, GDC-0941 is much more
PI3K-specific, whereas its effect on mTOR is negligible [26,44]. In
addition, GDC-0941 is currently used in clinical trials in cancer
patients (e.g. NCT00876109; NCT00960960). Since the involve-
ment of mTOR in the enhancement of DOX-induced apoptosis in
RD cells was unlikely (see Figure 4A and 4B), we precluded PI103
from in vivo studies and instead treated RD-transplanted nude
mice with GDC-0941 and/or DOX (for cooperative effect of
Figure 4. Inhibition of mTOR does not sensitize RD cells to DOX-induced apoptosis. A) and B) RD cells were treated for 24h with 1 mM
DOX and/or 1 mM everolimus (ever; respective left panels) or with 1 mM DOX and/or 20 mM LY294002 (respective right panels) or solvent. A) Annexin
V positive RD cells were analysed by FACS. Data represent mean+SEM of two independent experiments performed in duplicates. n.s. not significant
by Students t-test. B) Western blot analyses.
doi:10.1371/journal.pone.0052898.g004
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Figure S5).
In the experiment presented in Figure 5A, the animals were
treated with the drugs for a period of 22 days. In order to avoid
overlooking transient effects on apoptosis, the tumors of the
animals were harvested within 24 h after the last application of
either drug. As shown in Figure 5A, monotherapy with either
DOX or GDC-0941 over a period of 22 days significantly
attenuated tumor growth (Figure 5A; Table S2), without causing
any obvious side effects. Compared to the continuous low-dose
application of DOX, GDC-0941 had a more pronounced effect on
tumor growth inhibition. In fact, GDC-0941 completely stopped
tumor growth after 7 days of treatment (Figure 5A; Table S2).
However, the antitumor effects were not increased when tumors
were additionally treated with DOX (Figure 5A, Table S2). A
similar result was observed when a lower dose of GDC-0941 (i.e.
1/3 of the initial dose) was combined with DOX (Table S2).
Moreover, tumor regrowth was not different between the
treatment groups after withdrawal of the drugs (Table S3).
Although immunohistochemical analysis of paraffin-embedded
tumor sections did not reveal any significant difference in TUNEL
positive cells (data not shown), the combination increased the
percentage of cells positive for active caspase 3 when compared to
application of either DOX or GDC-0941 alone (Figure 5B). These
data demonstrated that the combination therapy consisting of
DOX plus GDC-0941 elevates caspase 3 activity in vivo. However,
this increase in caspase 3 activity caused by the combination
treatment does not translate into a cooperative suppression of
tumor growth.
Discussion
DOX is a potent anticancer drug employed in the therapy of
several solid tumors including sarcoma. Its mode of action is not
completely understood, but involves inhibition of TOP2A and
intercalation into DNA, which finally results in double strand
breaks and inhibition of DNA replication [45,46]. DOX also
interferes with apoptotic processes and mediates the release of cell-
damaging radicals [47].
Despite being one of the drugs of choice in sarcoma treatment,
DOX sometimes does not show any efficacy [10–12]. In addition,
it has a very high potential for cardiotoxicity, which is a limiting
factor of DOX therapy, particularly in children [13,14]. There-
fore, this drug remains a controversial treatment option in
sarcoma, especially in RMS, the most common sarcoma of
childhood.
We aimed at enhancing the efficacy of DOX in sarcoma cells.
We first applied several drugs with reported DOX-sensitizing
capacity in other cancer cells lines. 5-Aza, VPA, pioglitazone and
bortezomib were promising candidates as these drugs can enhance
TOP2A expression, which is an important determinant in DOX
responsiveness [48]. Indeed, in a pre-screen using HT1080 cells,
bortezomib and pioglitazone enhanced DOX-mediated antipro-
liferative and proapoptotic effects, respectively. Although these
drugs certainly deserve more investigations with respect to the
enhancement of DOX-induced antitumoral responses (e.g. pre-
treatment of the cells with the drugs; application of the drugs at
a higher dose; combination with lower or higher DOX concen-
trations), we focused on PI103, which simultaneously enhanced
DOX-induced proliferation inhibition, induction of apoptosis, and
activation of caspase 3 in all three sarcoma- and RMS-derived cell
lines investigated.
The PI3K/Akt/mTOR signaling pathway represents a promis-
ing target for therapeutic intervention, since it is abnormally
activated in many different human sarcoma types [1,49]. The
current focus in the clinics is on inhibition of mTOR. Besides
monotherapy with mTOR inhibitors, several combinations with
other agents including anthracyclines are being investigated in
sarcomas. Among these are ridaforolimus and DOX
(NCT00288431), or temsirolimus plus pegylated liposomal DOX
in resistant solid malignancies or recurrent sarcoma
(NCT00703170; NCT00949325).
However, pure mTOR inhibition (alone or in combination with
other cytostatics) should be carefully reconsidered, because
inhibition of mTOR results in activation of Akt in some tumor
entities including RMS [42,43,50] (this study, see Figure 4).
Therefore, the better choice for the treatment of these tumors
could be either dual PI3K/mTOR inhibitors targeting both PI3K
(thus preventing Akt activation) and mTOR, or pure PI3K
inhibitors.
Dual PI3K/mTOR inhibitors can sensitize a variety of cancer
cell lines to the treatment with DOX, but only one study reports
combined treatment effects in sarcoma. In the latter study, the
combination of the dual PI3K/mTOR inhibitor NVP-BEZ235
plus DOX resulted in a potentiation of antiproliferative effects
in vitro [51]. However, neither a NVP-BEZ235-mediated enhance-
ment of DOX-induced proapoptotic effects nor antitumoral effects
in in vivo experiments were reported [51].
Our results now show that the PI103-mediated sensitization of
sarcoma cells to DOX treatment also involves activation of Bax,
cytochrome c release, and activation of caspase 3. A similar
cooperative proapoptotic effect has been observed in glioblastoma
and neuroblastoma cells [24,25]. In neuroblastoma, the co-
operative proapoptotic effect of DOX and PI103 resulted in
upregulation of Noxa and Bim, which correlated with increased
Bax/Bak conformational change, loss of mitochondrial membrane
potential, cytochrome c release, caspase activation, and caspase-
dependent apoptosis [25]. Furthermore, as in our study on
sarcoma, sensitization to DOX-induced apoptosis in glioblastoma
was mainly due to inhibition of PI3K, but not of mTOR [24].
These data suggest that the molecular mechanism resulting in
PI103-mediated sensitization of sarcoma to DOX is similar to the
chemosensitization of neuroblastoma and glioblastoma and
involves the activation of several proteins of the mitochondrial
apoptosis pathway.
Since the reason for the combined effect of PI103 and DOX on
the mitochondrial apoptosis pathway activation is still unknown,
we addressed several questions: First, we wanted to know whether
PI103-mediated inhibition of PI3K/Akt activity may decrease the
expression of MDR1 and MRP1, ultimately resulting in accumu-
lation of DOX in tumor cells. This was indeed the case as shown
by our experiments. However, the accumulation did not enhance
DOX mediated proapoptotic effects.
Secondly, we investigated whether the sensitization of PI103 to
DOX-mediated apoptosis involved mTOR inhibition. Our
experiments performed with the pure mTOR inhibitor everolimus
clearly argues against a role of mTOR in the sensitization process,
because this drug increased neither DOX-induced numbers of
Annexin V-positive cells nor caspase 3 activity. Instead, everolimus
induced Akt activity in RD cells.
Finally, we investigated whether the drug combination resulted
in any cooperative proapoptotic and antitumoral effect in vivo. For
combination treatment we used GDC-0941, which is an orally
available PI3K inhibitor with almost no mTOR modulating
effects. Indeed, the in vivo experiments demonstrated that the
combination of GDC-0941 plus DOX significantly increased the
numbers of caspase 3 positive cells. This indicates that PI3K
inhibition in combination with DOX increases proapoptotic
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further impact tumor growth or tumor regrowth when compared
to GDC-0941 alone.
The lack of a distinct cooperative suppression of tumor growth
by DOX plus GDC-0941 in vivo despite the synergistic induction
of apoptosis in vitro and the increase in caspase 3 cleavage in vivo in
response to the combination treatment points to a more complex
setting in vivo. A possible explanation for the lack of a cooperative
antitumoral effect may be factors provided by the tumor
microenvironment that transiently or permanently influence the
drug response of tumor cells. In addition, tumor hypoxia may have
an impact on the efficacy of the combination treatment that
becomes relevant in vivo. Reasons such as poor drug penetration
into tumor cells due to limited resorption, inefficient transport to
the tumor via blood vessels or inefficient transportation from the
vessels into the tumor tissue are less likely because both DOX and
GDC-0941 showed antitumor activity when applied alone.
Additional studies, also using other orally available inhibitors of
the PI3K axis, are required to answer the question whether DOX
plus GDC-0941 act in concert to suppress RMS growth in vivo.
Supporting Information
Figure S1 DOX plus PI103 results in induction of early and late
apoptosis. Annexin V positive cells in the living cell fractions of the
cell lines RD (A), TP5014 (B) and HT1080 (C) were distinguished
according to the positivity of both Annexin V and PI. As
demonstrated, the treatment of DOX plus PI103 increased the
Figure 5. GDC-0941 inhibits tumor growth and increases DOX-mediated effects on caspase 3 activity. A) Inhibition of RD tumor growth
(in %) in nude mice treated with 1.2 mg/kg DOX (i.p. every third day for 22 days; n=19), 75 mg/kg GDC-0941 (orally every day for 22 days; n=9), the
combination of both drugs (n=12) at the time points indicated. Vehicle-treated animals served a controls (n=18). B) Caspase 3 positive cells (in %) in
tumors of nude mice isolated after 22 days of treatment with DOX and/or GDC-0941 or solvent. Data represent mean+SEM. *P,0.05 by ANOVA/
Tukey’s testing.
doi:10.1371/journal.pone.0052898.g005
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Figure S2 Apoptosis induced by DOX plus PI103 is caspase-
dependent. RD cells were treated for 24 h with 1 mM DOX or
3 mM PI103 or 1 mM DOX plus 3 mM PI103 with or without
20 mM of the broad-range caspase inhibitor zVAD.fmk. Apoptosis
was analyzed by FACS of Annexin V positive cells. The data
shows that zVAD.fmk blocked apoptosis upon combined treat-
ment with DOX and PI103, demonstrating caspase dependency.
Statistical difference was analyzed by Student’s t-test.
(TIF)
Figure S3 Pretreatment with PI103 further strengthened the
antiproliferative effects of DOX. The preincubation of the cells for
12 h with 3 mM PI103 (‘‘PI103 [3 mM]preinc.’’) resulted in
a significant increase of the antiproliferative effect of 0.5 mM
DOX in RD (A), TP5014 (B) and HT1080 (C) cells. In this setting,
the antiproliferative effect was superior to that caused by a 24-
hours co-incubation with the drugs in all three cell lines (please
compare results to the BrdU data shown in Figure 1B of the main
manuscript). Comparisons were made with ANOVA/Tukey’s
testing. *P,0.05 compared to cells treated with solvent; #P,0.05
compared to cells treated with either drug alone.
(TIF)
Figure S4 Activation of Bax after treatment TP5014 and
HT1080 cells with PI103 and/or DOX. TP5014 (A) and
HT1080 (B) cells were treated with 3 mM PI103 and 1 mM
DOX for 24 h and Bax activity was analysed by Western Blot.
Whereas a treatment with DOX marginally changed the
conformational stage of Bax in HT1080 cells, the effect on Bax
activation was enhanced in both cell lines when the drugs were
combined.
(TIF)
Figure S5 GDC-0941 sensitizes RD cells to DOX-induced
apoptosis. RD cells were treated for 48 h with 1 mM DOX or
10 mM GDC-0941 or 1 mM DOX plus 10 mM GDC-0941.
Apoptosis was analyzed by FACS of Annexin V positive cells. The
data shows that GDC-0941 sensitizes RD cells to DOX-induced
apoptosis. Data represent mean+SEM of one experiment
performed in triplicates. Comparisons were made with AN-
OVA/Tukey’s testing. *P,0.05 compared to cells treated with
solvent; #P,0.05 compared to cells treated with either drug
alone.
(TIF)
Table S1 Primary and secondary antibodies for Western Blot.
(DOC)
Table S2 Significance of tumor growth inhibition after treat-
ment with either DOX (1.2 mg/kg), GDC-0941 (75 mg/kg or
25 mg/kg) or combination of the drugs. Sizes of 18 vehicle-
treated, 19 DOX-treated, 9 GDC-0941-treated and 12 DOX plus
GDC-0941-treated tumors were used to calculate the significance
of changes in growth after a 7, 14 or 21 days treatment with
75 mg/kg GDC-0941 and/or 1.2 mg/kg DOX. For the study
using 25 mg/kg GDC-0941 and/or 1.2 mg/kg DOX the sizes of
4 vehicle-treated, 6 DOX-treated, 6 GDC-0941-treated and 6
DOX plus GDC-0941-treated tumors were used to calculate the
significance of changes in growth after a 7 and 14 days treatment
with the drugs. P values were calculated by ANOVA/Tukey’s
method and adjusted for tumor size differences at the onset of the
treatment.
(DOC)
Table S3 Significance of tumor regrowth after treatment with
either DOX (1.2 mg/kg), GDC-0941 (75 mg/kg) or combination
of the drugs. Sizes of 6 vehicle-treated, 4 DOX-treated, 4 GDC-
0941-treated and 4 DOX plus GDC-0941-treated tumors were
used to calculate the significance of changes in tumor regrowth
after a 21 days treatment with 75 mg/kg GDC-0941 and/or
1.2 mg/kg DOX. The observation period after treatment end was
20 days. P values were calculated by ANOVA/Tukey’s method
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